Form 4: Travere Therapeutics Director Brinkley Ruth Williams Reports Acquisition of Shares and Stock Options

Director Brinkley Ruth Williams reports acquiring 6,500 shares of common stock and 19,500 stock options in Travere Therapeutics, Inc.

Summary

• On May 8, 2024, Brinkley Ruth Williams, a director of Travere Therapeutics, Inc., acquired 6,500 shares of common stock.
• These shares were acquired at a price of $0.
• Following the transaction, Williams directly owns 19,250 shares of common stock.
• Williams also acquired 19,500 stock options with an exercise price of $6.82, exercisable starting May 8, 2025, and expiring on May 7, 2034.
• These options were also acquired at a price of $0.
• The acquisition was part of an automatic equity grant under the company's 2018 Equity Incentive Plan for non-employee directors.
• The equity award vests over a one-year period.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects a routine transaction indicating continued alignment between the director and the company, with no immediate negative implications.

Positives

• The acquisition of shares and options by a director signals confidence in the company's future prospects.
• The equity grant aligns the director's interests with those of the shareholders.

Future Outlook

The document does not contain specific forward-looking statements, but the equity grant suggests a continued relationship between the director and the company.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency regarding the transactions of company insiders. This filing indicates standard compensation practices for non-employee directors.

Comparison to Industry Standards

• Equity compensation for board members is a common practice across the pharmaceutical and biotechnology industries.
• Companies like BioMarin Pharmaceutical and Vertex Pharmaceuticals also utilize stock options and restricted stock units as part of their director compensation packages.
• The vesting schedule of one year is fairly standard for director equity grants.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it aligns the director's interests with the company's performance.

Key Dates